NEW YORK – German cellular analytics firm Evorion Biotechnologies said on Tuesday that it has formed a strategic partnership with Jüke Systemtechnik and closed a financing round for an undisclosed amount to support commercialization of Evorion's cellular analysis platform.
Münster-based Evorion said that new and existing investors, including Jüke, participated in the financing round, with Jüke becoming an Evorion shareholder.
Altenberge-based Jüke will assume commercial-scale production of Evorion's CellCity instruments and will be "actively involved in further engineering and optimization activities," the companies said in a statement.
The CellCity platform in its current form comprises a cell incubator, an array chip with gel encapsulation, and software to enable high-throughput, massively-parallel single-cell analysis, or "functional phenomics," according to Evorion. Researchers can use the platform for cell interaction analysis, functional genomics, and in-depth cell population studies, among other applications.
"In Evorion's effort to expand commercialization of the CellCity system, the collaboration with Jüke plays an essential role to ensure commercial instrument production and continuous optimization of quality and supply chain," Evorion Biotechnologies CEO Sebastian Bühren said in a statement. "In the development of next-generation products and platforms, the outstanding development and engineering expertise of Jüke will be utilized for transfer into commercial production already at an early stage."